Expressing both CEP-1 and Fibβ36-52 antibodies prior to symptom onset was associated with a significantly higher risk of developing rheumatoid arthritis (OR 40.4; 95% CI 19.8-82.3).
Case-Control (n=1,714)
Does the presence of specific antibodies against citrullinated peptides precede the onset of rheumatoid arthritis symptoms?
The development of an immune response toward citrullinated peptides expands over time, with specific antibodies like CEP-1 and Fibβ36-52 strongly predicting the onset of rheumatoid arthritis.
Odds Ratio: 40.4 (95% CI 19.8–82.3)
OBJECTIVE: The presence of antibodies against cyclic citrullinated peptides has been demonstrated to precede the onset of symptoms of rheumatoid arthritis (RA) by several years. The aim of this study was to analyze antibodies against 10 citrullinated autoantigen-derived peptides for reactivity before the onset of RA symptoms. METHODS: A case-control study was conducted within the Medical Biobank of Northern Sweden. The study was performed in 409 individuals, 386 of whom donated 717 blood samples before the onset of symptoms of RA (pre-patients). The median period of time predating the onset of RA was 7.4 years. A total of 1,305 population-based control subjects were also studied. Antibodies to 10 citrullinated peptides, fibrinogen α573 (Fibα573), Fibα591, Fibβ36-52, Fibβ72, Fibβ74, α-enolase (citrullinated α-enolase peptide 1 CEP-1), triple-helical type II collagen peptide C1 (citC1III), filaggrin, vimentin 2-17 (Vim2-17), and Vim60-75, were analyzed using a microarray system. RESULTS: The fluorescence intensity of antibodies against Fibβ36-52, Fibβ74, CEP-1, citC1III, and filaggrin was significantly increased in pre-patients compared with controls (P<0.001). The levels of the earliest-detectable antibodies (Fibα591 and Vim60-75) fluctuated over time, with only a slight increase after the onset of disease. The frequency of antibodies against Fibβ36-52, CEP-1, and filaggrin increased gradually, reaching the highest levels before symptom onset. The frequency of a cluster of antibodies, citC1III, Fibα573, and Fibβ74, increased only slightly before the onset of symptoms but increased prominently after disease onset. The odds ratio for the development of RA in individuals expressing both CEP-1 and Fibβ36-52 antibodies (using data from samples obtained <3.35 years predating symptom onset) was 40.4 (95% confidence interval 19.8-82.3) compared with having either antibody alone. CONCLUSION: Development of an immune response toward citrullinated peptides is initially restricted but expands with time to induce a more specific response, with levels, particularly those of antibodies against CEP-1, Fibβ36-52, and filaggrin, increasing during the predating time period closer to the onset of symptoms.
Brink et al. (2013) conducted a case-control in Rheumatoid arthritis (n=1,714). Expression of both CEP-1 and Fibβ36-52 antibodies vs. Having either antibody alone was evaluated on Development of rheumatoid arthritis (OR 40.4, 95% CI 19.8-82.3). Expressing both CEP-1 and Fibβ36-52 antibodies prior to symptom onset was associated with a significantly higher risk of developing rheumatoid arthritis (OR 40.4; 95% CI 19.8-82.3).